Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.63B 8.44B 7.82B 7.2B 13.61B 921B 13.87B 93.21B 36.56B 452B 36.15B 35.36B 1,563B P/E 2026 *
-16.2x
P/E 2027 * -33.4x
Enterprise Value 9.37B 8.22B 7.62B 7.01B 13.25B 897B 13.51B 90.76B 35.6B 441B 35.2B 34.43B 1,522B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 6.75x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-2.58%
1 week-31.77%
Current month-28.43%
1 month-23.27%
3 months-24.28%
6 months-28.60%
Current year-28.26%
1 week 56.11
Extreme 56.11
86.74
1 month 56.11
Extreme 56.11
86.74
Current year 56.11
Extreme 56.11
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Chairman

7,670 0.0046%
06-30Fiscal year

Director

42,224 0.0255%
06-30Free

Director

7,670 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-2.58%-31.77%+33.37%+33.03% 9.63B
+0.44%+1.41%+4.25%+10.81% 50.73B
-1.57%-3.18%+379.41%+593.37% 39.73B
-0.14%+0.77%+29.61%-5.50% 34.69B
+1.76%-1.78%+20.55%+53.38% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.93%-1.01% - - 16.8B
-1.49%-6.18%+65.50%+120.53% 15.37B
+0.78%+1.16%+15.53%+17.32% 13.78B
-0.97%-2.83%+11.09%-33.29% 12.85B
Average -0.60%-3.76%+62.47%+91.25% 25.35B
Weighted average by Cap. -0.32%-1.46%+79.25%+120.53%

Financials

2026 *2027 *
Net sales 889M 780M 722M 665M 1.26B 85.1B 1.28B 8.61B 3.38B 41.79B 3.34B 3.27B 144B 1.41B 1.24B 1.15B 1.06B 2B 135B 2.04B 13.68B 5.36B 66.4B 5.3B 5.19B 229B
Net income -594M -521M -482M -444M -840M -56.85B -856M -5.75B -2.26B -27.92B -2.23B -2.18B -96.41B -292M -256M -237M -218M -413M -27.97B -421M -2.83B -1.11B -13.73B -1.1B -1.07B -47.43B
Net Debt -252M -221M -205M -189M -357M -24.17B -364M -2.44B -959M -11.87B -948M -927M -40.98B -86.16M -75.57M -69.99M -64.4M -122M -8.25B -124M -834M -327M -4.05B -324M -316M -13.99B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-13 US$56.75 -2.58% 5,096,062
26-07-10 US$58.25 -9.37% 11,444,106
26-07-09 US$64.27 -23.90% 20,447,626
26-07-08 US$84.46 -2.17% 2,280,833
26-07-07 US$86.33 +3.79% 2,646,707
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
58.25USD
Average target price
93.23USD
Spread / Average Target
+60.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock